Combination therapy with GB1211 and an anti-PD-L1 blocking antibody reduced tumor growth in an in vivo syngeneic model and increased the percentage of tumor infiltrating T lymphocytes. Conclusion: Our study suggests that Gal-3 can potentiate the PD-1/PD-L1 immune ...
After blocking PD-1/PD-L1, tumor cells can still counteract the activity of immune checkpoints and activate additional inhibitory pathways via expression of other immune checkpoints and their ligands within the tumor immune microenvironment [45]. For example, T cell immunoglobulin mucin-3 (Tim-3)...
little is known about the molecular basis underlying this accumulation and its potential as a target to ameliorate the ageing process. Here we show that senescent cells heterogeneously express the immune checkpoint protein programmed death-ligand
Splenocytes from these groups were then harvested and stained with an anti-Rat-IgG2b FITC antibody to determine if the PD-L1 blocking antibody was opsonizing the previously identified PD-L1+ subsets (Tregs, B cells, cDC1s, cDC2s, and Macrophages). The anti-PD-L1 blocking antibody was ...
Engineering CAR T cells to secrete PD-1-blocking antibody fragments at targeted sites such as the tumor microenvironment has been proposed [23]. However, it has also been suggested that ICBs in these settings can act indiscriminately and may be responsible for hyper-progressive disease states due...
sites, making it unstable and poorly secreted. As a splicing variant of PD-L1, PD-L1-vInt4 functions as bait in anti-PD-L1 antibody therapy, further contributing to drug resistance [104]. This finding sheds light on a novel mechanism of drug resistance against anti-PD-L1 antibodies. (Fig...
About BAVENCIO ® (avelumab) BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to ...
(2013). "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells" Clin Cancer Res 19(20): 5636-5646 in vivo blocking of PD-1/PD-L signaling Holmgaard, R. B., et al. (2013). "Indoleamine 2,3-dioxygenase is a critical resistance ...
(2013). "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells" Clin Cancer Res 19(20): 5636-5646 in vivo blocking of PD-1/PD-L signaling Holmgaard, R. B., et al. (2013). "Indoleamine 2,3-dioxygenase is a critical resistance ...
Despite resistance to anti-PD-1, they showed promising results post-trial (1 CR, 1 PR, and 2 SD). Based on the results of these 4 patients, we are confident in excluding the PD-1 antibody as part of antitumor efficacy in this therapeutic regimen. Treatment with PD-1 blocking antibodies...